Compare
Relmada Therapeutics, Inc. vs Journey Medical Corp vs Arbutus Biopharma Corp vs Pyxis Oncology, Inc.
| Latest fiscal year | Relmada Therapeutics, Inc. RLMD | Journey Medical Corp DERM | Arbutus Biopharma Corp ABUS | Pyxis Oncology, Inc. PYXS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $61.24M | $14.08M | $13.86M |
| Revenue growth (YoY) | n/a | +11.1% | +128.2% | -14.2% |
| Gross margin | n/a | 65.8% (computed) | n/a | 82.8% (computed) |
| Operating margin | n/a | -13.3% | -271.0% | -609.2% |
| Net margin | n/a | -18.7% | -237.9% | -574.5% |
| Net income | -$57.39M | -$11.43M | -$33.50M | -$79.62M |
| EPS (Diluted) | -$1.45 | -$0.47 | -$0.17 | -$1.28 |
| Operating cash flow | -$45.79M | -$12.44M | -$39.64M | -$63.50M |
| Free cash flow | n/a | n/a | -$39.64M | -$63.51M |
| Cash & equivalents | $3.50M | $24.09M | $18.01M | $15.42M |
| Total assets | $94.00M | $94.59M | $94.62M | $91.52M |
| Total liabilities | $7.49M | $62.74M | $18.04M | $38.11M |
| Shareholders' equity | $86.51M | $31.85M | $76.58M | $53.41M |
| Return on year-end equity | -66.3% | -35.9% | -43.7% | -149.1% |
| Shares outstanding | 73.33M | n/a | 192.53M | 62.69M |
Revenue, most recent five fiscal years
| Fiscal year | Relmada Therapeutics, Inc. | Journey Medical Corp | Arbutus Biopharma Corp | Pyxis Oncology, Inc. |
|---|---|---|---|---|
| Latest | $5.1K Ended 2013-08-31 | $61.24M Ended 2025-12-31 | $14.08M Ended 2025-12-31 | $13.86M Ended 2025-12-31 |
| 1 year earlier | $7.9K Ended 2012-08-31 | $55.13M Ended 2024-12-31 | $6.17M Ended 2024-12-31 | $16.15M Ended 2024-12-31 |
| 2 years earlier | n/a | $59.66M Ended 2023-12-31 | $18.14M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $71.00M Ended 2022-12-31 | $39.02M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $63.13M Ended 2021-12-31 | $10.99M Ended 2021-12-31 | n/a |